cytokine release syndrome
cytokine release syndrome
Explore linked clinical trials. Standard reference: MONDO:060000827 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-09 | NCT06806033 | |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-10-06 | NCT07657312 | |
| CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, acute myeloid leukemia, cytokine release syndrome, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 | 2026-10-02 | NCT07841002 | |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-28 | NCT06421675 | |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 4 | 2026-09-25 | NCT07609940 | |
| Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study | Hemic and Lymphatic Diseases, Inflammation, Lymphohistiocytosis, Hemophagocytic, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Skin and Connective Tissue Diseases, Systemic Inflammatory Response Syndrome, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, cytokine release syndrome, histiocytosis, immune system disorder, immunoproliferative disorder, iron metabolism disease, isolated hyperferritinemia, juvenile idiopathic arthritis, lymphatic system disorder, lymphoproliferative syndrome, macrophage activation syndrome, metabolic disease, musculoskeletal system disorder, non-Langerhans cell histiocytosis, rheumatic disorder, secondary hemophagocytic lymphohistiocytosis | Recruiting | Not stated | 2026-09-10 | NCT06339177 | |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp | Inflammation, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, Uveal Neoplasms, cytokine release syndrome, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Not yet recruiting | Phase 2 | 2026-09-03 | NCT07803562 | |
| Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome | Recruiting | Phase 1 / Phase 2 | 2026-08-31 | NCT05905328 | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | B-cell neoplasm, Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, poisoning, toxic encephalopathy | Active, not recruiting | Phase 1 | 2026-07-31 | NCT03696784 | |
| INfections in Patients Treated With CAR-T | B-cell neoplasm, B-cell non-Hodgkin lymphoma, Blood Protein Disorders, Hemic and Lymphatic Diseases, Infections, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not stated | 2026-07-20 | NCT07713511 | |
| Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | Blood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Enrolling by invitation | Not applicable | 2026-06-25 | NCT07499128 | |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-06-25 | NCT06447376 | |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) | COVID-19, Coronaviridae Infections, Infections, Inflammation, Mononegavirales infectious disease, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Paramyxoviridae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pneumovirus Infections, RNA Virus Infections, Respiration Disorders, Shock, Systemic Inflammatory Response Syndrome, adult acute respiratory distress syndrome, cytokine release syndrome, influenza, lung disorder, pneumonia, respiratory syncytial virus infectious disease, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 1 / Phase 2 | 2026-06-10 | NCT06684379 | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-06-10 | NCT03016377 | |
| Early Detection of Complications During Immunotherapy for Haematological Malignancy | Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Not applicable | 2026-05-15 | NCT06377059 | |
| Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis | Hemic and Lymphatic Diseases, Inflammation, Lymphohistiocytosis, Hemophagocytic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, histiocytosis, lymphatic system disorder, non-Langerhans cell histiocytosis | Not yet recruiting | Phase 3 | 2026-04-23 | NCT07497438 | |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-04-22 | NCT05972135 | |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, Tumor Virus Infections, cytokine release syndrome, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-03-30 | NCT07502118 | |
| Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, hemophagocytic syndrome | Recruiting | Early phase 1 | 2026-03-03 | NCT05306080 | |
| Jafron Cytokine Adsorber During Pediatric Open-Heart Surgeries | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome | Not yet recruiting | Not applicable | 2026-02-10 | NCT07393087 | |
| Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy | Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, plasma cell neoplasm | Recruiting | Not applicable | 2026-02-05 | NCT07390071 | |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) | Flaviviridae infectious disease, Flavivirus Infections, Infections, Inflammation, Mosquito-Borne Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Shock, Systemic Inflammatory Response Syndrome, arbovirus infection, cytokine release syndrome, dengue disease, dengue shock syndrome, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, macrophage activation syndrome, vector-borne disease, viral hemorrhagic fever, viral infectious disease | Active, not recruiting | Phase 2 | 2026-01-06 | NCT05611710 | |
| Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 | 2025-12-24 | NCT07166549 | |
| Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome | Recruiting | Phase 1 | 2025-09-11 | NCT07169487 | |
| CytOSorb TreatMent Of Critically Ill PatientS Registry | Acute-On-Chronic Liver Failure, Chemically-Induced Disorders, Digestive System Diseases, Disease Attributes, Drug Misuse, Drug Overdose, Hemic and Lymphatic Diseases, Hepatic Insufficiency, Infarction, Infections, Inflammation, Lymphohistiocytosis, Hemophagocytic, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Vasoplegic Syndrome, Prescription Drug Misuse, Respiration Disorders, Rhabdomyolysis, Sepsis, Shock, Shock, Cardiogenic, Systemic Inflammatory Response Syndrome, Vasoplegia, acute liver failure, adult acute respiratory distress syndrome, burn, cardiovascular disorder, cytokine release syndrome, heart disorder, histiocytosis, infectious disease, injury, ischemic disease, liver disorder, liver failure, lung disorder, lymphatic system disorder, muscle tissue disorder, musculoskeletal system disorder, myocardial infarction, myocardial ischemia, non-Langerhans cell histiocytosis, pancreas disorder, pancreatitis, psychiatric disorder, respiratory system disorder, substance-related disorder, toxic shock syndrome, vascular disorder | Recruiting | Not stated | 2025-09-11 | NCT05146336 |